Skip to main content

Notice for vanzacaftor, tezacaftor, deutivacaftor (Vertex Pharmaceuticals Australia Pty Ltd)

Active ingredients
vanzacaftor, tezacaftor, deutivacaftor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
tablet
Indication
Treatment of Cystic Fibrosis
Therapeutic area
Oncology

Help us improve the Therapeutic Goods Administration site